The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer

Poly (ADP-ribose) polymerase inhibitors (PARP inhibitor) is a new targeted drug for metastatic prostate cancer in which the patient has mutation on homologous repair gene including BRCA1/2 gene. This was first gene-based agent and there were more than 5 available drugs PARP inhibitors. Only 4 approved clinical use patients with from U.S. Food Drug Administration. review article deals overview of their future research fields.